All relevant data are within the paper and its Supporting Information files. Questions regarding the data may be sent to (<tsuchiya-tky@umin.net>).

Introduction {#sec001}
============

An epidemiologic difference is clearly observed in antineutrophil cytoplasmic antibody (ANCA) -associated vasculitides (AAV) between European and East Asian populations. In a population-based prospective study, microscopic polyangiitis (MPA) and myeloperoxidase (MPO) -ANCA-positive AAV (MPO-AAV) were the predominant subtypes (\>80%) in Japan, while granulomatosis with polyangiitis (GPA) and proteinase 3 (PR3) -ANCA-positive AAV (PR3-AAV) were the predominant subtypes (\>60%) in the UK \[[@pone.0154393.ref001]\]. Differences in the genetic backgrounds among populations may play a role in such epidemiologic differences.

Human leukocyte antigens (HLA) have been intensively investigated for association with susceptibility to a number of autoimmune diseases. With respect to AAV in the populations of European ancestry, candidate gene studies with relatively small sample sizes suggested an association of the *DR4-DQ7* haplotype with the predisposition to both GPA and MPA in the UK \[[@pone.0154393.ref002]\], of the *DR1-DQ1* haplotype with GPA in the UK \[[@pone.0154393.ref003]\], and of *DRB1\*04* with end-stage renal disease accompanied by GPA in Germany \[[@pone.0154393.ref004]\]. On the other hand, protective association of *DRB1\*13* has been detected for GPA in Germany \[[@pone.0154393.ref004]\] and in the Netherlands \[[@pone.0154393.ref005]\]. Subsequently, association of *DPB1\*04*:*01* with GPA has been reported in a moderately powered study in Germany \[[@pone.0154393.ref006]\].

Recently, two large-scale genome-wide association studies (GWAS) on AAV in European \[[@pone.0154393.ref007]\] and North American \[[@pone.0154393.ref008]\] populations detected the strongest associations in the major histocompatibility complex (*MHC*) region. In the European study, GPA and PR3-AAV showed the strongest association in the *HLA-DP* region, while MPA and MPO-AAV demonstrated the strongest association in the *HLA-DQ* region \[[@pone.0154393.ref007]\], which is generally in strong linkage disequilibrium (LD) with the *HLA-DR* region. Additionally, in the North American study (in which only GPA was studied), the strongest association was observed in the *HLA-DP* region. Using imputation, the investigators demonstrated that *DPB1\*04* is a risk allele group for GPA \[[@pone.0154393.ref008]\], supporting the results of a previous study in Germany \[[@pone.0154393.ref006]\].

Due to the rarity of AAV, few studies have examined the genetics in Asian populations. Our group has been conducting a nationwide multicenter collaborative study of AAV in Japan. Thus far, we have reported the association of *DRB1\*09*:*01* and *DQB1\*03*:*03*, which are in strong LD, with MPA and MPO-AAV \[[@pone.0154393.ref009]--[@pone.0154393.ref011]\]. Curiously, while these risk haplotypes are among the most frequent *HLA-class II* haplotypes in East Asian populations, these haplotypes are very rare in populations of European or African ancestry (Allele\*Frequencies in Worldwide Populations, <http://www.allelefrequencies.net/>) \[[@pone.0154393.ref012]\]. Thus, it is possible that ethnic differences in the genetic backgrounds may be related to the differences in the incidence of AAV subsets.

Another remarkable feature of AAV in Japan was recently reported. Unlike in European populations, approximately half of the patients who were classified into GPA according to the European Medicines Agency (EMEA) algorithm \[[@pone.0154393.ref013]\] were positive for MPO-ANCA \[[@pone.0154393.ref014]\]. Therefore, the comparison between Japanese and European populations of the genetic backgrounds of patients with GPA will be of interest. With respect to GPA in Japan, only one study with a very small sample size reported an association between GPA and *DR9*, and that study was performed before the EMEA algorithm was proposed \[[@pone.0154393.ref015]\]. Furthermore, 19.9% of Japanese AAV patients who were eligible for classification by the EMEA algorithm (based on ANCA positivity and symptoms and signs of AAV) nonetheless remained "unclassifiable" according to the EMEA algorithm \[[@pone.0154393.ref014]\]. Interestingly, 93.5% of these unclassifiable AAV patients were positive for MPO-ANCA, and 63.5% presented with interstitial lung disease (ILD) \[[@pone.0154393.ref014]\], suggesting that this group may constitute a unique subset in the AAV spectrum.

In the present study, we substantially increased the sample size of Japanese patients with AAV from those of our previous studies, and performed an extended association analysis on *DRB1* and *DPB1* with AAV in the Japanese population. Thus, the work described here allowed us to assess whether additional *DRB1* and *DPB1* predispositional or protective alleles exist for MPA and MPO-AAV, and whether *DRB1* and/or *DPB1* are associated with GPA and PR3-AAV. *HLA-DQA1* and *DQB1* were not genotyped in this study, because these loci are in strong LD with *DRB1*, making it highly difficult to distinguish associations of these alleles based on the current sample size. Our observations indicated that *DRB1\*13*:*02* was associated with protection against MPA and MPO-AAV. In agreement with a previous study in European populations, association of *DPB1\*04*:*01* with the predisposition to PR3-AAV, but not with MPO-AAV, was suggested in the Japanese population. Taken together with our previous observations (which demonstrated protective association of *DRB1\*13*:*02* with rheumatoid arthritis (RA) \[[@pone.0154393.ref016]\] and systemic lupus erythematosus (SLE) \[[@pone.0154393.ref017]\]), the haplotype carrying *DRB1\*13*:*02* was suggested to be a common protective factor against multiple autoimmune diseases.

Materials and Methods {#sec002}
=====================

Patients and controls {#sec003}
---------------------

Four hundred and sixty-eight Japanese patients with AAV and 596 healthy controls, including the 116 patients with MPO-AAV and 265 controls reported in our previous study \[[@pone.0154393.ref011]\], were recruited at the institutes participating in the Research Committee on Intractable Vasculitides and in the Research Group on Progressive Renal Diseases, both organized by the Ministry of Health, Labour, and Welfare of Japan, research groups organized by Sagamihara Hospital, National Hospital Organization, and the Tokyo Medical and Dental University. Information on the patients and healthy individuals is shown in [S1 Table](#pone.0154393.s005){ref-type="supplementary-material"}. The patients were classified according to the EMEA algorithm \[[@pone.0154393.ref013]\]. Two hundred and eighty-five cases were classified as MPA, 92 as GPA, 56 as EGPA, and 35 were considered unclassifiable AAV. Among all patients, 377 and 62 were positive for MPO-ANCA and PR3-ANCA by ELISA, respectively.

Ethics statement {#sec004}
----------------

This study was reviewed and approved by the Ethics Committees of the University of Tsukuba, National Hospital Organization Sagamihara Hospital, the Tokyo Medical and Dental University, Okayama University, Kyoto University, Kagawa University, Juntendo University, St. Marianna University, Kanazawa University, University of Tokyo, Kyorin University, Saitama Medical Center Hospital, the University of Miyazaki, Toho University, Kobe University Hospital, Kitano Hospital, Shimane University, Nagoya City University, Ehime University, Jichi Medical University, Kyoto Prefectural University, Tokyo Medical University Hachioji Medical Center, Kitasato University Hospital, Hamamatsu University, National Hospital Organization Shimoshizu National Hospital, Tenri Hospital, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Hyogo University, Kawasaki Municipal Hospital, Sendai Shakaihoken Hospital, Tokyo Women's Medical College, Kyoundo Hospital, Tokyo Metropolitan Komagome Hospital, Ome Municipal General Hospital, Teikyo University, Hokkaido University, Fukuoka University, Okayama Saiseikai General Hospital, Aichi Medical University, Asahikawa Medical University, Kyushu University, Iwate Prefectural Central Hospital, and Nagasaki University. Written informed consent was obtained from all participants, except for some healthy individuals who donated blood (for use in medical genetics studies) before 2001, that is, prior to the implementation by the Japanese government of the Ethics Guidelines for Human Genome/Gene Analysis Research. From such healthy individuals, verbal informed consent for the genetics study had been obtained. In accordance with the Japanese Ethical Guidelines for Human Genome/Gene Analysis Research, such samples were anonymized in an unlinkable fashion, and were included in this study after review and approval by the Ethics Committee of the University of Tsukuba. This study was conducted according to the principles expressed in the Declaration of Helsinki.

*HLA* allele typing {#sec005}
-------------------

*HLA-DRB1* and *DPB1* genotypes were determined at the "four-digit" high-resolution level by polymerase chain reaction (PCR) -microtiter plate hybridization or PCR-sequence-specific oligonucleotide probes using WAKFlow HLA typing kits (Wakunaga Pharmaceutical Co., Ltd., Osaka, Japan). Amino acid sequences encoded by each *DRB1* or *DPB1* allele were based on the IMGT/HLA Database (<http://www.ebi.ac.uk/ipd/imgt/hla/>) \[[@pone.0154393.ref018]\].

Statistical analysis {#sec006}
--------------------

*DRB1* and *DPB1* alleles with frequencies ≥ 0.01 in healthy controls were examined for their association with AAV subsets by Fisher\'s exact test in 2 x 2 contingency tables. When one of the cell counts was zero, odds ratio (OR) and 95% confidence interval (CI) were calculated with Haldane's modification by adding 0.5 to each cell count. Correction for multiple testing was done by Bonferroni correction. Statistical tests for 30 alleles (*DRB1*: 21, *DPB1*: 9) were carried out for each of five AAV subsets (MPA, GPA, EGPA, MPO-AAV, and PR3-AAV). Thus, the significance level was set at α = 3.3x10^-4^ (0.05/150). When a strong protective association with one allele is present in a multiallelic locus like *HLA*, the predispositional association of the other alleles tends to be overestimated, and the protective association of the other alleles tends to be underestimated. In order to confirm whether the apparent predispositional allele is really predispositional, and to detect additional predispositional or protective alleles, the relative predispositional effects (RPE) method was employed under the allele model, by consecutively excluding the most strongly associated allele from the next-round analysis, until no allele showed P~RPE~ \< 0.05 \[[@pone.0154393.ref019]\]. Conditional logistic regression analysis was performed to detect the primary associated allele from the *DRB1* and *DPB1* alleles in LD. Association of each DRβ1 and DPβ1 amino acid variant with frequencies ≥ 0.01 in the healthy controls was tested by logistic regression analysis under the additive model. Statistical tests in 57 polymorphic amino acid positions (DRβ1: 38, DPβ1: 19) were conducted for each of two AAV subsets (MPO-AAV and PR3-AAV). Thus, in this analysis, the significance level was set at α = 4.4x10^-4^ (0.05/114) using Bonferroni correction. When three or more amino acid variants are present at the same position, only the P value for the comparison between the most strongly associated amino acid and all other amino acid variants is shown. Statistical power in this study, calculated with the PS (Power and Sample Size Calculation) program, is shown in [S2 Table](#pone.0154393.s006){ref-type="supplementary-material"}.

Results {#sec007}
=======

HLA-DRB1 {#sec008}
--------

Association of *DRB1* alleles with AAV was tested using clinical disease classification according to the EMEA algorithm ([Table 1](#pone.0154393.t001){ref-type="table"} and [S3 Table](#pone.0154393.s007){ref-type="supplementary-material"}) as well as by ANCA specificity ([Table 2](#pone.0154393.t002){ref-type="table"} and [S4 Table](#pone.0154393.s008){ref-type="supplementary-material"}). This analysis permitted determination of the association of *DRB1\*09*:*01* with AAV in a larger sample size than in our previous studies, along with assessment of the association of other predispositional or protective *DRB1* alleles with MPA and MPO-AAV. Predispositional association of the *DRB1\*09*:*01* allele was confirmed in MPO-AAV (P = 2.1x10^-4^, OR = 1.57, 95%CI 1.24--1.98). In MPA, a trend for the association with this allele was detected (P = 7.7x10^-4^, OR = 1.56, 95%CI 1.21--2.01), although the association failed to achieve statistical significance after Bonferroni correction. Comparison of carrier frequency (dominant model) demonstrated essentially the same results ([S3](#pone.0154393.s007){ref-type="supplementary-material"} and [S4](#pone.0154393.s008){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0154393.t001

###### *HLA-DRB1* allele frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls.

![](pone.0154393.t001){#pone.0154393.t001g}

  *DRB1*   MPA (2n = 570)   EGPA (2n = 112)     GPA (2n = 184)   HC (2n = 1192)                                                                                                              
  -------- ---------------- ------------------- ---------------- ---------------- --------------------------------------------------------- ------- ----------- ------------------- -------- ------------
  01:01    41 (7.2)         1.24 (0.83--1.85)   0.30             8 (7.1)          1.23 (0.58--2.63)                                         0.53    14 (7.6)    1.32 (0.73--2.40)   0.41     70 (5.9)
  04:01    6 (1.1)          0.74 (0.29--1.88)   0.66             0 (0.0)          0.30 (0.02--5.00)[^b^](#t001fn003){ref-type="table-fn"}   0.39    2 (1.1)     0.76 (0.17--3.31)   1.0      17 (1.4)
  04:03    14 (2.5)         0.81 (0.43--1.51)   0.54             4 (3.6)          1.19 (0.42--3.40)                                         0.77    3 (1.6)     0.53 (0.16--1.75)   0.47     36 (3.0)
  04:05    65 (11.4)        0.89 (0.65--1.21)   0.49             8 (7.1)          0.53 (0.25--1.11)                                         0.097   24 (13.0)   1.03 (0.65--1.64)   0.91     151 (12.7)
  04:06    12 (2.1)         0.64 (0.33--1.22)   0.22             3 (2.7)          0.81 (0.25--2.68)                                         1.0     7 (3.8)     1.17 (0.51--2.65)   0.66     39 (3.3)
  04:07    6 (1.1)          1.05 (0.39--2.80)   1.0              0 (0.0)          0.42 (0.02--7.14)[^b^](#t001fn003){ref-type="table-fn"}   0.61    2 (1.1)     1.08 (0.24--4.87)   1.0      12 (1.0)
  04:10    9 (1.6)          1.11 (0.49--2.50)   0.83             3 (2.7)          1.90 (0.55--6.59)                                         0.24    4 (2.2)     1.54 (0.51--4.62)   0.51     17 (1.4)
  08:02    21 (3.7)         1.34 (0.77--2.34)   0.30             1 (0.9)          0.32 (0.04--2.34)                                         0.35    13 (7.1)    2.67 (1.38--5.17)   0.0064   33 (2.8)
  08:03    41 (7.2)         0.98 (0.67--1.45)   1.0              9 (8.0)          1.11 (0.54--2.27)                                         0.71    15 (8.2)    1.13 (0.64--2.00)   0.65     87 (7.3)
  09:01    125 (21.9)       1.56 (1.21--2.01)   7.7E-04          24 (21.4)        1.51 (0.94--2.44)                                         0.10    35 (19.0)   1.30 (0.87--1.95)   0.19     182 (15.3)
  11:01    16 (2.8)         1.61 (0.83--3.11)   0.16             3 (2.7)          1.53 (0.45--5.23)                                         0.45    5 (2.7)     1.56 (0.58--4.18)   0.38     21 (1.8)
  12:01    17 (3.0)         0.73 (0.42--1.29)   0.34             4 (3.6)          0.88 (0.31--2.49)                                         1.0     2 (1.1)     0.26 (0.06--1.09)   0.054    48 (4.0)
  12:02    8 (1.4)          0.72 (0.32--1.63)   0.56             2 (1.8)          0.92 (0.22--3.97)                                         1.0     1 (0.5)     0.28 (0.04--2.07)   0.24     23 (1.9)
  13:02    25 (4.4)         0.47 (0.30--0.74)   6.3E-04          6 (5.4)          0.58 (0.25--1.35)                                         0.29    9 (4.9)     0.53 (0.26--1.06)   0.084    106 (8.9)
  14:03    17 (3.0)         1.33 (0.72--2.45)   0.41             2 (1.8)          0.78 (0.18--3.34)                                         1.0     1 (0.5)     0.24 (0.03--1.75)   0.16     27 (2.3)
  14:05    12 (2.1)         0.73 (0.38--1.43)   0.43             1 (0.9)          0.31 (0.04--2.26)                                         0.36    3 (1.6)     0.56 (0.17--1.86)   0.47     34 (2.9)
  14:06    4 (0.7)          0.69 (0.22--2.16)   0.60             2 (1.8)          1.79 (0.40--8.09)                                         0.34    2 (1.1)     1.08 (0.24--4.87)   1.0      12 (1.0)
  14:54    24 (4.2)         1.54 (0.90--2.64)   0.11             4 (3.6)          1.30 (0.45--3.74)                                         0.55    3 (1.6)     0.58 (0.18--1.92)   0.47     33 (2.8)
  15:01    28 (4.9)         0.71 (0.46--1.10)   0.14             10 (8.9)         1.34 (0.68--2.67)                                         0.43    9 (4.9)     0.71 (0.35--1.43)   0.42     81 (6.8)
  15:02    71 (12.5)        1.16 (0.85--1.58)   0.34             13 (11.6)        1.07 (0.59--1.97)                                         0.75    25 (13.6)   1.28 (0.81--2.03)   0.32     130 (10.9)
  16:02    1 (0.2)          0.17 (0.02--1.33)   0.073            1 (0.9)          0.89 (0.11--6.88)                                         1.0     3 (1.6)     1.63 (0.46--5.83)   0.44     12 (1.0)

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. Significance level was set at α = 3.3x10^-4^ by applying Bonferroni correction.

^a^ n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).

^b^ OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

10.1371/journal.pone.0154393.t002

###### *HLA-DRB1* allele frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls.

![](pone.0154393.t002){#pone.0154393.t002g}

  *DRB1*   MPO-AAV (2n = 754)   PR3-AAV (2n = 124)   HC (2n = 1192)                                                                                          
  -------- -------------------- -------------------- ---------------- -------- ----------- --------------------------------------------------------- ------- ------------
  01:01    56 (7.4)             1.29 (0.89--1.85)    0.19             0.30     8 (6.5)     1.11 (0.52--2.35)                                         0.84    70 (5.9)
  04:01    7 (0.9)              0.65 (0.27--1.57)    0.40             0.30     2 (1.6)     1.13 (0.26--4.96)                                         0.70    17 (1.4)
  04:03    18 (2.4)             0.79 (0.44--1.39)    0.48             0.33     2 (1.6)     0.53 (0.13--2.21)                                         0.57    36 (3.0)
  04:05    74 (9.8)             0.75 (0.56--1.01)    0.059            0.020    17 (13.7)   1.10 (0.64--1.88)                                         0.78    151 (12.7)
  04:06    24 (3.2)             0.97 (0.58--1.63)    1.0              0.79     1 (0.8)     0.24 (0.03--1.76)                                         0.17    39 (3.3)
  04:07    7 (0.9)              0.92 (0.36--2.35)    1.0              0.82     2 (1.6)     1.61 (0.36--7.29)                                         0.39    12 (1.0)
  04:10    12 (1.6)             1.12 (0.53--2.35)    0.85             1.0      3 (2.4)     1.71 (0.50--5.93)                                         0.43    17 (1.4)
  08:02    36 (4.8)             1.76 (1.09--2.85)    0.023            0.044    2 (1.6)     0.58 (0.14--2.43)                                         0.77    33 (2.8)
  08:03    51 (6.8)             0.92 (0.64--1.32)    0.72             0.47     14 (11.3)   1.62 (0.89--2.94)                                         0.11    87 (7.3)
  09:01    166 (22.0)           1.57 (1.24--1.98)    **2.1E-04**\*    0.0012   23 (18.5)   1.26 (0.78--2.04)                                         0.36    182 (15.3)
  11:01    19 (2.5)             1.44 (0.77--2.70)    0.26             0.33     5 (4.0)     2.34 (0.87--6.33)                                         0.090   21 (1.8)
  12:01    20 (2.7)             0.65 (0.38--1.10)    0.13             0.077    3 (2.4)     0.59 (0.18--1.93)                                         0.62    48 (4.0)
  12:02    6 (0.8)              0.41 (0.17--1.01)    0.054            0.035    2 (1.6)     0.83 (0.19--3.58)                                         1.0     23 (1.9)
  13:02    30 (4.0)             0.42 (0.28--0.64)    **2.3E-05**\*    \-       9 (7.3)     0.80 (0.40--1.63)                                         0.62    106 (8.9)
  14:03    21 (2.8)             1.24 (0.69--2.20)    0.55             0.65     0 (0.0)     0.17 (0.01--2.81)[^b^](#t002fn003){ref-type="table-fn"}   0.10    27 (2.3)
  14:05    13 (1.7)             0.60 (0.31--1.14)    0.13             0.097    4 (3.2)     1.14 (0.40--3.25)                                         0.78    34 (2.9)
  14:06    8 (1.1)              1.05 (0.43--2.59)    1.0              1.0      1 (0.8)     0.80 (0.10--6.20)                                         1.0     12 (1.0)
  14:54    28 (3.7)             1.35 (0.81--2.26)    0.29             0.35     5 (4.0)     1.48 (0.57--3.85)                                         0.40    33 (2.8)
  15:01    43 (5.7)             0.83 (0.57--1.21)    0.39             0.22     6 (4.8)     0.70 (0.30--1.63)                                         0.57    81 (6.8)
  15:02    97 (12.9)            1.21 (0.91--1.60)    0.19             0.39     14 (11.3)   1.04 (0.58--1.87)                                         0.88    130 (10.9)
  16:02    5 (0.7)              0.66 (0.23--1.87)    0.62             0.46     0 (0.0)     0.38 (0.02--6.44)[^b^](#t002fn003){ref-type="table-fn"}   0.62    12 (1.0)

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. RPE: relative predispositional effect. RPE analysis was performed by excluding *DRB1\*13*:*02* allele from cases and controls. P values considered significant after Bonferroni correction (\<3.3x10^-4^) are shown in bold with an asterisk.

^a^ n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).

^b^ OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

In addition, significant protective association with *DRB1\*13*:*02* was newly detected against MPO-AAV (allele model, P = 2.3x10^-5^, OR = 0.42, 95%CI 0.28--0.64, dominant model, P = 1.1x10^-5^, OR = 0.39, 95%CI 0.25--0.60) and MPA (dominant model, P = 2.7x10^-4^, OR = 0.43, 95%CI 0.26--0.68) ([Table 2](#pone.0154393.t002){ref-type="table"}, [S3](#pone.0154393.s007){ref-type="supplementary-material"} and [S4](#pone.0154393.s008){ref-type="supplementary-material"} Tables). In order to exclude potential over- and underestimation caused by strongly associated alleles in a multiallelic locus such as *HLA*, the RPE method was employed. Thus, association of the other alleles was tested after excluding the most strongly associated *DRB1\*13*:*02* allele from the patients and controls. In MPO-AAV, the tendency toward positive association of *DRB1\*09*:*01* was still observed (P~RPE~ = 0.0012) ([Table 2](#pone.0154393.t002){ref-type="table"}), suggesting that the predispositional association of *DRB1\*09*:*01* with MPO-AAV was not a secondary phenomenon caused by protective association with *DRB1\*13*:*02*.

With respect to other AAV subsets, a tendency toward positive association was detected between GPA and *DRB1\*08*:*02* (P = 0.0064, OR = 2.67, 95%CI 1.38--5.17) ([Table 1](#pone.0154393.t001){ref-type="table"}). Essentially identical results were observed in the analysis of carrier frequency (dominant model) ([S3](#pone.0154393.s007){ref-type="supplementary-material"} and [S4](#pone.0154393.s008){ref-type="supplementary-material"} Tables).

HLA-DPB1 {#sec009}
--------

Next, association of *HLA-DPB1* with clinical classification ([Table 3](#pone.0154393.t003){ref-type="table"} and [S5 Table](#pone.0154393.s009){ref-type="supplementary-material"}) and with ANCA specificity ([Table 4](#pone.0154393.t004){ref-type="table"} and [S6 Table](#pone.0154393.s010){ref-type="supplementary-material"}) was examined. Protective association of *DPB1\*04*:*01* with MPO-AAV was detected (allele frequency: P = 2.1x10^-4^, OR = 0.40, 95%CI 0.24--0.67, carrier frequency: P = 1.2x10^-4^, OR = 0.38, 95%CI 0.22--0.64) ([Table 4](#pone.0154393.t004){ref-type="table"} and [S6 Table](#pone.0154393.s010){ref-type="supplementary-material"}). Essentially the same results were observed in MPA ([Table 3](#pone.0154393.t003){ref-type="table"} and [S5 Table](#pone.0154393.s009){ref-type="supplementary-material"}). In RPE analysis, no significant association of the other alleles was detected in MPO-AAV ([Table 4](#pone.0154393.t004){ref-type="table"}).

10.1371/journal.pone.0154393.t003

###### *HLA-DPB1* allele frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls.

![](pone.0154393.t003){#pone.0154393.t003g}

  *DPB1*   MPA (2n = 570)   EGPA (2n = 112)     GPA (2n = 184)   HC (2n = 1186)                                                                                                            
  -------- ---------------- ------------------- ---------------- ---------------- --------------------------------------------------------- ------- ----------- ------------------- ------ ------------
  02:01    155 (27.2)       1.19 (0.94--1.49)   0.14             23 (20.5)        0.82 (0.51--1.32)                                         0.49    50 (27.2)   1.19 (0.83--1.68)   0.36   284 (23.9)
  02:02    24 (4.2)         1.33 (0.79--2.24)   0.33             4 (3.6)          1.12 (0.39--3.19)                                         0.78    4 (2.2)     0.67 (0.24--1.90)   0.64   38 (3.2)
  03:01    29 (5.1)         1.36 (0.84--2.19)   0.21             4 (3.6)          0.94 (0.33--2.66)                                         1.0     6 (3.3)     0.85 (0.36--2.03)   0.84   45 (3.8)
  04:01    19 (3.3)         0.51 (0.31--0.85)   0.0090           2 (1.8)          0.27 (0.07--1.11)                                         0.057   14 (7.6)    1.22 (0.67--2.21)   0.52   75 (6.3)
  04:02    73 (12.8)        1.44 (1.05--1.97)   0.025            14 (12.5)        1.40 (0.77--2.53)                                         0.31    19 (10.3)   1.13 (0.67--1.88)   0.68   110 (9.3)
  05:01    183 (32.1)       0.77 (0.62--0.95)   0.015            43 (38.4)        1.01 (0.68--1.51)                                         1.0     64 (34.8)   0.87 (0.63--1.20)   0.41   452 (38.1)
  09:01    64 (11.2)        1.10 (0.80--1.52)   0.56             11 (9.8)         0.95 (0.50--1.82)                                         1.0     19 (10.3)   1.00 (0.60--1.67)   1.0    122 (10.3)
  13:01    6 (1.1)          0.56 (0.23--1.40)   0.31             5 (4.5)          2.47 (0.92--6.66)                                         0.076   1 (0.5)     0.29 (0.04--2.16)   0.35   22 (1.9)
  14:01    8 (1.4)          0.79 (0.35--1.79)   0.69             0 (0.0)          0.24 (0.01--4.00)[^b^](#t003fn003){ref-type="table-fn"}   0.25    5 (2.7)     1.55 (0.58--4.16)   0.38   21 (1.8)

HC: healthy controls, OR: odds ratio, CI: confidence interval, P values were calculated by Fisher's exact test. Significance level was set at α = 3.3x10^-4^ by applying Bonferroni correction.

^a^ n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).

^b^ OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

10.1371/journal.pone.0154393.t004

###### *HLA-DPB1* allele frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls.

![](pone.0154393.t004){#pone.0154393.t004g}

  *DPB1*   MPO-AAV (2n = 754)   PR3-AAV(2n = 124)   HC (2n = 1186)                                                                                         
  -------- -------------------- ------------------- ---------------- ------- ----------- --------------------------------------------------------- ------- ------------
  02:01    200 (26.5)           1.15 (0.93--1.41)   0.22             0.45    29 (23.4)   0.97 (0.63--1.50)                                         1.0     284 (23.9)
  02:02    29 (3.8)             1.21 (0.74--1.98)   0.45             0.61    3 (2.4)     0.75 (0.23--2.46)                                         0.79    38 (3.2)
  03:01    37 (4.9)             1.31 (0.84--2.04)   0.25             0.36    4 (3.2)     0.85 (0.30--2.39)                                         1.0     45 (3.8)
  04:01    20 (2.7)             0.40 (0.24--0.67)   **2.1E-04**\*    \-      14 (11.3)   1.89 (1.03--3.45)                                         0.057   75 (6.3)
  04:02    91 (12.1)            1.34 (1.00--1.80)   0.056            0.094   14 (11.3)   1.24 (0.69--2.25)                                         0.42    110 (9.3)
  05:01    255 (33.8)           0.83 (0.69--1.00)   0.059            0.011   45 (36.3)   0.93 (0.63--1.36)                                         0.77    452 (38.1)
  09:01    88 (11.7)            1.15 (0.86--1.54)   0.37             0.50    9 (7.3)     0.68 (0.34--1.38)                                         0.35    122 (10.3)
  13:01    10 (1.3)             0.71 (0.33--1.51)   0.47             0.37    0 (0.0)     0.21 (0.01--3.45)[^b^](#t004fn003){ref-type="table-fn"}   0.26    22 (1.9)
  14:01    11 (1.5)             0.82 (0.39--1.71)   0.72             0.59    3 (2.4)     1.38 (0.40--4.68)                                         0.49    21 (1.8)

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. RPE: relative predispositional effect. In MPO-AAV, RPE was performed by excluding *DPB1\*04*:*01*. P value considered significant after Bonferroni correction (\<3.3x10^-4^) is shown in bold with an asterisk.

^a^ n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).

^b^ OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

When the association between *DPB1* and GPA/PR3-AAV was examined, *DPB1\*04*:*01* (the risk allele for GPA in European populations) also showed a trend for association with predisposition to PR3-AAV in the Japanese population (P = 0.057, OR = 1.89, 95%CI: 1.03--3.45) ([Table 4](#pone.0154393.t004){ref-type="table"}). An association with *DPB1\*04*:*01* was not observed for GPA (P = 0.52) ([Table 3](#pone.0154393.t003){ref-type="table"}).

Conditional analysis of the *DRB1\*13*:*02* and *DPB1\*04*:*01* associations in AAV subsets {#sec010}
-------------------------------------------------------------------------------------------

*DRB1\*13*:*02* and *DPB1\*04*:*01* alleles, which are both negatively associated with MPO-ANCA, were in moderate LD *(r*^*2*^ = 0.44). We therefore made an attempt to dissect these associations using logistic regression analysis ([Table 5](#pone.0154393.t005){ref-type="table"}).

10.1371/journal.pone.0154393.t005

###### Conditional logistic regression analysis between *DRB1\*13*:*02* and *DPB1\*04*:*01* in AAV subsets.

![](pone.0154393.t005){#pone.0154393.t005g}

  *HLA* allele      unconditioned   conditioned on *DRB1\*13*:*02*   conditioned on *DPB1\*04*:*01*                                
  ----------------- --------------- -------------------------------- -------------------------------- ------------------- -------- -------------------
  MPA                                                                                                                              
  *DRB1\*13*:*02*   0.0011          0.47 (0.30--0.73)                N/A                              N/A                 0.033    0.53 (0.29--0.93)
  *DPB1\*04*:*01*   0.011           0.51 (0.30--0.84)                0.57                             0.83 (0.42--1.59)   N/A      N/A
  GPA                                                                                                                              
  *DRB1\*13*:*02*   0.076           0.53 (0.25--1.01)                N/A                              N/A                 0.0066   0.29 (0.11--0.68)
  *DPB1\*04*:*01*   0.52            1.21 (0.65--2.11)                0.015                            2.55 (1.17--5.48)   N/A      N/A
  MPO-AAV                                                                                                                          
  *DRB1\*13*:*02*   6.6E-05         0.43 (0.28--0.64)                N/A                              N/A                 0.024    0.55 (0.32--0.91)
  *DPB1\*04*:*01*   4.4E-04         0.41 (0.24--0.66)                0.16                             0.64 (0.33--1.18)   N/A      N/A
  PR3-AAV                                                                                                                          
  *DRB1\*13*:*02*   0.54            0.80 (0.37--1.54)                N/A                              N/A                 0.028    0.36 (0.14--0.86)
  *DPB1\*04*:*01*   0.042           1.86 (0.99--3.30)                0.0021                           3.48 (1.55--7.78)   N/A      N/A

OR: odds ratio, CI: confidence interval, N/A: not applicable; P value, OR, and 95%CI and adjusted P value, OR, and 95%CI on the indicated *HLA* allele were calculated by logistic regression analysis under the additive model.

In MPO-AAV, the protective association of *DPB1\*04*:*01* lost significance when conditioned on *DRB1\*13*:*02* (unconditioned P = 4.4x10^-4^, P~adjusted~ = 0.16), while the tendency toward association of *DRB1\*13*:*02* remained when conditioned on *DPB1\*04*:*01* (unconditioned P = 6.6x10^-5^, P~adjusted~ = 0.024). These results suggested that the protective association of *DPB1\*04*:*01* with MPO-AAV was secondary, and instead actually reflected LD with *DRB1\*13*:*02*.

In contrast, although the association of *DPB1\*04*:*01* was barely detectable in PR3-AAV (unconditioned P = 0.042), the tendency became apparent when conditioned on *DRB1\*13*:*02* (P~adjusted~ = 0.0021). This observation suggested that *DPB1\*04*:*01*, the risk allele for European GPA, also may contribute to susceptibility to PR3-AAV in the Japanese population. Similarly, *DRB1\*13*:*02* showed a tendency toward association after conditioning on *DPB1\*04*:*01* (P~adjusted~ = 0.028). The direction of association was opposite for *DPB1\*04*:*01* (unconditioned OR = 1.86, OR~adjusted~ = 3.48) compared to *DRB1\*13*:*02* (unconditioned OR = 0.54, OR~adjusted~ = 0.36). Thus, it is likely that the associations of *DPB1\*04*:*01* and *DRB1\*13*:*02* to PR3-AAV were attenuated by each other due to LD, and therefore were underestimated before conditioning. The same tendency also was observed in GPA after conditioning on the opposing allele. These results suggested that the protective effect of *DRB1\*13*:*02* may be present across all subsets of AAV, while the predispositional effect of *DPB1\*04*:*01* may be present in PR3-AAV and GPA.

Effects of *DRB1* genotypes on MPO-AAV {#sec011}
--------------------------------------

Next, we calculated the OR for MPO-AAV with respect to *DRB1* genotypes. To do this, we classified each *DRB1* allele into three categories corresponding to *DRB1\*09*:*01*, *DRB1\*13*:*02*, and any remaining alleles (denoted by N for "neutral"). The results are shown in [S1 Fig](#pone.0154393.s001){ref-type="supplementary-material"}. When compared with genotype N/N as the referent, *DRB1\*09*:*01/N* was associated with predisposition (OR = 1.65, P = 0.0013) and \**13*:*02/N* with protection (OR = 0.45, P = 0.0019). Significant association was not detected for \**09*:*01/09*:*01* or \**13*:*02/13*:*02*, presumably due to the small number of individuals homozygous for these alleles.

Association of amino acid variations in DRβ1 {#sec012}
--------------------------------------------

Finally, we investigated the association of each amino acid variation in the DRβ1 and DPβ1 proteins with MPO-AAV and PR3-AAV using logistic regression analysis under the additive model. In DRβ1, 71E demonstrated the strongest association with the protection from MPO-AAV (P = 2.6x10^-5^, OR = 0.41) ([S2A Fig](#pone.0154393.s002){ref-type="supplementary-material"}). When conditioned on 71E, only 67F showed marginal predispositional association (P~adjusted~ = 4.9x10^-4^, OR = 1.46) ([S2B Fig](#pone.0154393.s002){ref-type="supplementary-material"}). When conditioned on both 71E and 67F, no further significant association was detected ([S2C Fig](#pone.0154393.s002){ref-type="supplementary-material"}).

With respect to DPβ1, significant association (P = 4.1x10^-4^, OR = 0.47) of 36A and 55A, which are in absolute LD, with MPO-ANCA was detected ([S3A Fig](#pone.0154393.s003){ref-type="supplementary-material"}). When conditioned on 36A, no further significant association was detected ([S3B Fig](#pone.0154393.s003){ref-type="supplementary-material"}).

Finally, because our observations indicated that the association of *DPB1\*04*:*01* with MPO-AAV may be secondarily caused by *DRB1\*13*:*02*, we examined the association of DPβ1 amino acids by conditioning on *DRB1\*13*:*02*. With such conditioning, the association in DPβ1 amino acids was no longer significant ([S3C Fig](#pone.0154393.s003){ref-type="supplementary-material"}).

Significant association with PR3-ANCA was not detected for DRβ1 nor DPβ1 amino acids, probably due to the small sample size.

Discussion {#sec013}
==========

In this study, we performed a detailed analysis of the association of *HLA-DRB1* and *DPB1* using the "four-digit" high-resolution allele typing on 468 Japanese patients with AAV and 596 healthy controls. To our knowledge, this sample size is (to date) the largest among the AAV genetics studies reported for East Asian populations. In addition, the present work represents the first study to examine *DPB1* association with GPA in East Asian populations. In view of the remarkable differences in the epidemiology and genetic background between the European and East Asian populations \[[@pone.0154393.ref001]\], our study adds valuable information to the genetics research of AAV.

We confirmed the previously reported association of *DRB1\*09*:*01* with MPO-AAV \[[@pone.0154393.ref009]--[@pone.0154393.ref011]\] in an extended association study. Moreover, this study identified *DRB1\*13*:*02* as a protective allele for MPO-AAV and MPA. Although the protective effect of *DRB1\*13* has previously been reported for GPA or PR3-AAV in European populations \[[@pone.0154393.ref004],[@pone.0154393.ref005]\], to our knowledge protective association with MPA or MPO-AAV has not previously been clearly demonstrated. This discrepancy likely reflects a lack of detection power due to the lower prevalence of MPO-AAV in the European populations.

Notably, we recently reported the protective association of *DRB1\*13*:*02* against RA \[[@pone.0154393.ref016]\] and SLE \[[@pone.0154393.ref017]\]. Thus, in sharp contrast to *DRB1\*09*:*01* (which also has been reported to be associated with predisposition to RA \[[@pone.0154393.ref020],[@pone.0154393.ref021]\], SLE \[[@pone.0154393.ref021]\], type 1 diabetes \[[@pone.0154393.ref022]\], and myasthenia gravis \[[@pone.0154393.ref023]\]), *DRB1\*13*:*02* or other allele(s) in strong LD appears to have a protective effect against multiple autoimmune rheumatic diseases.

A recent study in a Chinese population reported association of *DRB1\*11*:*01* with susceptibility to MPA, but association of *DRB1\*09*:*01* was not detected \[[@pone.0154393.ref024]\]. In the present study, although we detected a trend toward increased frequency of *DRB1\*11*:*01* in some subgroups of AAV (Tables [1](#pone.0154393.t001){ref-type="table"} and [2](#pone.0154393.t002){ref-type="table"}), this trend did not achieve statistical significance. We were unable to replicate association of *DRB1\*14*:*54* with protection against overall AAV, nor *DRB1\*12*:*02* association with predisposition to GPA in the Chinese \[[@pone.0154393.ref024]\]. The reasons for these discrepancies are not clear, although differences in *HLA* allele frequencies in the general population might play a role. In the Chinese study, the allele frequency of *DRB1\*11*:*01* in the control group was 6.5% \[[@pone.0154393.ref024]\], which was considerably higher than the 1.8% allele frequency in the Japanese ([Table 1](#pone.0154393.t001){ref-type="table"}).

In the *MHC* region, strong LD is detected. As for *DRB1*, strong LD is observed with *DQB1*. *DRB1\*09*:*01* and *DRB1\*13*:*02* were in nearly absolute LD with *DQB1\*03*:*03* (r^2^ = 0.83) and *DQB1\*06*:*04* (r^2^ = 0.89), respectively, in our healthy controls. This pattern makes it highly difficult to distinguish the association of the *DRB1* alleles from that of the *DQB1* alleles with the present sample size. Therefore, our observations only indicate that the major genetic factor for MPA/MPO-AAV is present in the *HLA-DR/DQ* region. This result is consistent with the finding from the European GWAS, which demonstrated the strongest association signal for MPA/MPO-AAV at a single nucleotide polymorphism (SNP) close to the *DQB1* locus (rs5000634) \[[@pone.0154393.ref007]\]. To fine-map the primary associated allele, the association study would need to be conducted using a larger sample size.

With regards to *DPB1*, the present study suggested the possibility that the *DPB1\*04*:*01* allele may be associated with PR3-AAV in the Japanese population, as in Caucasian populations \[[@pone.0154393.ref006],[@pone.0154393.ref008]\]. In contrast, *DPB1\*04*:*01* was protective against MPO-AAV, although this protection was a secondary effect caused by LD with *DRB1\*13*:*02*. In view of the striking population difference in the *DPB1\*04*:*01* allele frequency in populations of Japanese (6.3%) ([Table 3](#pone.0154393.t003){ref-type="table"}) and European extraction (e.g., 42.5% in USA) (Allele\*Frequencies in Worldwide Populations <http://www.allelefrequencies.net/>) \[[@pone.0154393.ref012]\], *DPB1\*04*:*01* may in part account for the epidemiologic difference in the prevalence of PR3-AAV. In fact, as already pointed out by Watts et al. \[[@pone.0154393.ref025]\], population allele frequency of *DPB1\*04*:*01* is higher in northern Europe than in southern Europe ([S4 Fig](#pone.0154393.s004){ref-type="supplementary-material"}) based on Allele\*Frequencies in Worldwide Populations <http://www.allelefrequencies.net/>) \[[@pone.0154393.ref012]\]. On the other hand, the population allele frequencies of *DRB1\*09*:*01* and *DQB1\*03*:*03* are low in both northern and southern Europe; no apparent north-south gradient is observed. Elucidation of whether the north-south gradient of *HLA* alleles can account for the geographic variation in incidence of MPA and MPO-AAV in Europe will require identification of *HLA* alleles that can explain the GWAS signal of rs5000634 \[[@pone.0154393.ref007]\] in European populations.

When the associations identified in the present work were analyzed with respect to the amino acid sequences, DRβ1 67F was associated with predisposition to, and 71E with protection against, MPO-AAV. Among the *DRB1* alleles having allele frequencies \> 1% in the Japanese population, 67F is encoded by *DRB1\*08*:*02*, \**09*:*01*, \**11*:*01*, and \**12*:*02*, while 71E is encoded only by *DRB1\*13*:*02*. Among the alleles encoding 67F, the frequencies of all except for *DRB1\*12*:*02* were nominally or significantly higher in patients with MPO-AAV ([Table 2](#pone.0154393.t002){ref-type="table"}). Because amino acids at positions 67 and 71 influence antigenic peptide binding pockets P7 and P4 (respectively) \[[@pone.0154393.ref026]\], it is possible that the antigenic peptide motifs of these alleles may be involved in the molecular mechanism of association. On the other hand, the fact that *DRB1\*09*:*01* and *DRB1\*13*:*02* are associated with susceptibility to or protection against multiple autoimmune diseases with apparently no shared autoantigens suggests that a role is played by the non-*HLA* alleles carried by these *HLA* haplotypes (rather than the antigenic peptide specificity). These hypotheses are not mutually exclusive, and will require further investigation.

In the present study, associations generally appeared to be more prominent with ANCA specificity than with clinical classification (e.g., *DPB1\*04*:*01* association with MPA: P = 0.0063, OR = 0.48; with MPO-AAV: P = 1.2x10^-4^, OR = 0.38; with GPA: P = 0.86, OR = 1.07; with PR3-AAV: P = 0.12, OR = 1.71), consistent with the results obtained by GWAS in European populations \[[@pone.0154393.ref007]\]. In this regard, it would be interesting to test the *HLA* association of the two potentially unique subsets in Japan, MPO-ANCA-positive GPA and MPO-ANCA-positive unclassifiable AAV \[[@pone.0154393.ref014]\], when sufficient numbers of samples become available. In the present study, both of these AAV subsets were included in MPO-ANCA-positive subset; even after excluding unclassifiable AAV from the analyses, the association of *DRB1\*09*:*01* (P = 1.8x10^-4^) and *DRB1\*13*:*02* (P = 1.4x10^-4^) with MPO-AAV remained significant.

One of the most interesting findings in our study is that the haplotype carrying *DRB1\*13*:*02*, which we have reported to have protective association against RA \[[@pone.0154393.ref016]\] and SLE \[[@pone.0154393.ref017]\], is also protective against MPA and MPO-AAV, suggesting that this haplotype carries a common protective allele with shared efficacy against different autoimmune diseases. Identification (by fine mapping of the SNPs and deep sequencing) of the allele(s) responsible for the protection, and of these allele(s)' molecular mechanism(s) would not only lead to better understanding of the etiopathogenesis of autoimmune diseases, but also to new molecular targets that could be effective for multiple autoimmune diseases.

There are several limitations in this study. Due to the rarity of AAV, this study is not an independent replication of our previous studies \[[@pone.0154393.ref009]--[@pone.0154393.ref011]\], but is instead an extension study. A replication study on a completely independent case-control set will be required to establish the *HLA* associations with AAV in the Japanese.

The sample sizes of GPA, EGPA, and PR3-AAV are especially small, due to the low prevalence of these subsets in the Japanese. Therefore, our results on these subsets suffer from low detection power ([S2 Table](#pone.0154393.s006){ref-type="supplementary-material"}), and significant associations may emerge when the sample size becomes larger, especially for the alleles which showed uncorrected P values \< 0.05 but did not achieve significance following Bonferroni correction.

Another limitation is that we only focused on *DRB1* and *DPB1*, and did not examine *DQB1* (which is in strong LD with *DRB1*) or other *HLA* and non-*HLA* alleles. Therefore, at this point, we cannot exclude the possibility that the associations detected for *DRB1* and *DPB1* alleles may only tag other causal alleles. Such a possibility should be investigated in the future using high-density SNP mapping, imputation, and/or sequencing of the *MHC* region.

In conclusion, in addition to confirming the predispositional association of *DRB1\*09*:*01* with MPO-AAV, this study identified the protective association of *DRB1\*13*:*02* against MPA and MPO-AAV in the Japanese population. Taken together with our previous observations, *DRB1\*13*:*02* itself (or another allele in LD with *DRB1\*13*:*02*) was suggested to be a common protective factor against multiple autoimmune diseases.

Supporting Information {#sec014}
======================

###### Association of *HLA-DRB1* genotypes with MPO-AAV.

Each *DRB1* allele was classified into *DRB1\*09*:*01* (predispositional), *DRB1\*13*:*02* (protective), or any of the remaining alleles (denoted by N for neutral). Odds ratio, 95% confidence interval, and P value of each genotype group were calculated against *N/N*. The numbers of patients and controls in each group are shown below.
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###### 

Click here for additional data file.

###### Association of DRβ1 amino acid variations with MPO-AAV.

Association of each amino acid residue in the DRβ1 protein with MPO-AAV was analyzed using logistic regression analysis under the additive model. Amino acid residues with frequencies ≥ 0.01 in healthy controls were examined for their association. The significance level was set at α = 4.4x10^-4^ using Bonferroni correction. (A) Unconditioned P values (closed circles) are shown. When three or more amino acid variants are present at the same position, only the P value for the comparison between the most strongly associated amino acid and all other amino acid variants is shown. (B,C) P values conditioned on 71E (grey circles) and P values conditioned on 71E and 67F (open circles) were calculated for the amino acid variants shown in S2A Fig.

(PPTX)

###### 

Click here for additional data file.

###### Association of DPβ1 amino acid variations with MPO-AAV.

Association of each amino acid residue in the DPβ1 protein with MPO-AAV was analyzed using logistic regression analysis under the additive model. Amino acid residues with frequencies ≥ 0.01 in healthy controls were examined for their association. The significance level was set at α = 4.4x10^-4^ using Bonferroni correction. (A) Unconditioned P values (closed circles) are shown. When three or more amino acid variants are present at the same position, only the P value for the comparison between the most strongly associated amino acid and all other amino acid variants is shown. (B,C) P values conditioned on 36A (grey circles) and P values conditioned on *DRB1\*13*:*02* (open circles) were calculated for the amino acid variants shown in S3A Fig.
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###### 

Click here for additional data file.

###### North-south gradient of population *DPB1\*04*:*01* allele frequency in Europeans.

*DPB1* allele frequencies in European populations, aligned from north to south according to the latitude. The data were derived from Allele\*Frequencies in Worldwide Populations (<http://www.allelefrequencies.net/>) \[[@pone.0154393.ref012]\].
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Click here for additional data file.

###### EMEA classification and ANCA specificity of the subjects.

SD: standard deviation, F: female, M: male, NA: not available.

(DOCX)

###### 

Click here for additional data file.

###### Power calculation in the present study.

NA: not available. Power calculation was conducted in each AAV subset and healthy controls (2n = 1192) using the PS (Power and Sample Size Calculation) program. Significance level was set at α = 3.3x10^-4^ (0.05/150).

(DOCX)

###### 

Click here for additional data file.

###### *HLA-DRB1* allele carrier frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls (dominant model).

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. P values considered significant after Bonferroni correction (\< 3.3x10^-4^) are shown in bold with an asterisk. ^a^n (%): number and percentage of individuals who carry the allele (either homozygotes or heterozygotes) among the total number of individuals in each group. ^b^OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.
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Click here for additional data file.

###### *HLA-DRB1* allele carrier frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls (dominant model).

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. P values considered significant after Bonferroni correction (\< 3.3x10^-4^) are shown in bold with an asterisk. ^a^n (%): number and percentage of individuals who carry the allele (either homozygotes or heterozygotes) among the total number of individuals in each group. ^b^OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

(DOCX)

###### 

Click here for additional data file.

###### *HLA-DPB1* allele carrier frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls (dominant model).

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. Significance level was set at α = 3.3x10^-4^ by applying Bonferroni correction. ^a^n (%): number and percentage of individuals who carry the allele (either homozygotes or heterozygotes) among the total number of individuals in each group. ^b^OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

(DOCX)

###### 

Click here for additional data file.

###### *HLA-DPB1* allele carrier frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls (dominant model).

HC: healthy controls, OR: odds ratio, CI: confidence interval. P values were calculated by Fisher's exact test. P values considered significant after Bonferroni correction (\< 3.3x10^-4^) are shown in bold with an asterisk. ^a^n (%): number and percentage of individuals who carry the allele (either homozygotes or heterozygotes) among the total number of individuals in each group. ^b^OR and 95% CI were calculated using Haldane's method when one of the cell counts was zero.

(DOCX)

###### 

Click here for additional data file.
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